title: The effect of hepatic or renal impairment on the pharmacokinetics of edivoxetine, a selective norepinephrine transporter reuptake inhibitor.
abstract: OBJECTIVE
  To assess the impact of hepatic or renal impairment on the pharmacokinetics (PK) of edivoxetine.
  
  
  METHODS
  Two separate multi-center, open-label studies with males and females were conducted. Subjects were categorized according to their hepatic function, determined by the Child-Pugh classification, or renal function, determined by creatinine clearance using the Cockcroft-Gault equation. Subjects received a single dose of 18 mg in the hepatic impairment study or 6 mg in the renal impairment study. Noncompartmental PK parameters were computed from the edivoxetine plasma concentration-time data.
  
  
  RESULTS
  In the hepatic study, the geometric least squares mean (GLSM) and 90 % confidence interval (CI) of the ratio [impaired : normal] of area under the concentration versus time curve from time zero to infinity (AUC0-∞; h × ng/mL) was 1.24 (0.93, 1.64) in the mild, 1.60 (1.21, 2.12) in the moderate, and 1.70 (1.28, 2.24) in the severe group. In the renal impairment study, the GLSM (90 % CI) of the ratio [impaired : normal] of AUC0-∞ was 1.13 (0.73, 1.73) in mild, 1.90 (1.28, 2.82) in moderate, 1.55 (0.94, 2.55) in severe, and 1.03 (0.66, 1.59) in ESRD groups. Overall, the GLSM of the ratio [impaired : normal] of Cmax was slightly less than or approximately 1 across the hepatic and renal impairment groups. Across both studies, there were no clinically significant changes in vital signs and laboratory values, the adverse events were mild in severity and mostly related to nervous system and gastrointestinal disorder-related events.
  
  
  CONCLUSIONS
  PK changes in subjects with hepatic or renal impairment were of small magnitude and did not appear to impact overall subject tolerability. Daily dosing of edivoxetine in a larger population of impaired subjects, including those with dual impairment, would aid in establishing edivoxetine tolerability and PK in a clinical practice scenario.
authors: Lilly Corporate Center, Eli Lilly and Company, Indianapolis, IN, 46285, USA, wkielbasa@lilly.com.
authors: William
authors: W
authors: Kielbasa
authors: Eshetu
authors: E
authors: Tesfaye
authors: Debra
authors: D
authors: Luffer-Atlas
authors: Malcolm I
authors: MI
authors: Mitchell
authors: Michael A
authors: MA
authors: Turik
mesh_terms: D018759:Adrenergic Uptake Inhibitors / Q000097:blood / Q000493:pharmacokinetics*; D000328:Adult; D000368:Aged; D005260:Female; D006801:Humans; D008107:Liver Diseases / Q000097:blood*; D008297:Male; D008875:Middle Aged; D009025:Morpholines / Q000097:blood / Q000493:pharmacokinetics*; D010626:Phenylethyl Alcohol / Q000031:analogs & derivatives* / Q000097:blood / Q000493:pharmacokinetics; D051437:Renal Insufficiency / Q000097:blood*
chemical_list: D018759:Adrenergic Uptake Inhibitors; D009025:Morpholines; C568831:alpha-((5-fluoro-2-methoxyphenyl)methyl)-alpha-(tetrahydro-2H-pyran-4-yl)-2-morpholinemethanol; D010626:Phenylethyl Alcohol
references: J Child Adolesc Psychopharmacol. 2013 Apr;23(3):200-7
references: 23607409
references: Clin Pharmacol Ther. 2009 Mar;85(3):305-11
references: 19020495
references: J Psychiatr Res. 2010 Apr;44(6):356-63
references: 19909980
references: Major Probl Clin Surg. 1964;1:1-85
references: 4950264
references: J Psychiatr Res. 2011 Jun;45(6):748-55
references: 21511276
references: Br J Surg. 1973 Aug;60(8):646-9
references: 4541913
references: J Child Adolesc Psychopharmacol. 2012 Aug;22(4):269-76
references: 22849510
references: Clin Pharmacol Ther. 2009 Nov;86(5):553-6
references: 19776735
references: Clin Pharmacol Ther. 2008 Jun;83(6):898-903
references: 18388866
references: Pharmacol Ther. 2006 Jan;109(1-2):1-11
references: 16085315